Category Press Releases

Agios Secures EU Approval for PYRUKYND® (Mitapivat) to Treat Adults with Thalassaemia, Announces Avanzanite Bioscience

Agios Secures EU Approval for PYRUKYND® (mitapivat) to Treat Adults Living with Thalassaemia, Announces Avanzanite Bioscience Avanzanite Bioscience B.V. has announced a major milestone in the treatment of rare blood disorders following the European Commission’s approval of PYRUKYND® (mitapivat) for…

Read MoreAgios Secures EU Approval for PYRUKYND® (Mitapivat) to Treat Adults with Thalassaemia, Announces Avanzanite Bioscience

Enhertu® Receives CHMP Backing for EU Approval in Previously Treated HER2-Positive Metastatic Solid Tumors

Enhertu® Receives CHMP Recommendation for EU Approval in HER2-Positive Metastatic Solid Tumors Enhertu has received a positive recommendation for approval in the European Union from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency for…

Read MoreEnhertu® Receives CHMP Backing for EU Approval in Previously Treated HER2-Positive Metastatic Solid Tumors

OPTIMA Trial Data Presented at ASCO Support Prosigna-Guided Chemotherapy Decision-Making in Breast Cancer

Veracyte to Present Practice-Changing Oncology Data at ASCO 2026 Highlighting Advances in Breast and Prostate Cancer Genomic Testing Veracyte announced that major new clinical data involving its Prosigna Breast and Decipher Prostate genomic tests will be presented during the 2026…

Read MoreOPTIMA Trial Data Presented at ASCO Support Prosigna-Guided Chemotherapy Decision-Making in Breast Cancer

InSphero AG Acquires PhenoVista Biosciences, Inc. to Strengthen Advanced 3D Cell-Based Assay Solutions

InSphero AG has acquired PhenoVista Biosciences, Inc. to strengthen its advanced 3D cell-based assay capabilities and expand translational research solutions. InSphero AG has announced the acquisition of PhenoVista Biosciences, Inc., a strategic move aimed at expanding capabilities in advanced drug…

Read MoreInSphero AG Acquires PhenoVista Biosciences, Inc. to Strengthen Advanced 3D Cell-Based Assay Solutions

CONMED Corporation Appoints Celine Martin and Jeff Mirviss to Board of Directors

CONMED Corporation has appointed Celine Martin and Jeff Mirviss to its Board of Directors, strengthening the company’s leadership and strategic expertise. CONMED Corporation has announced the appointment of two seasoned healthcare industry leaders, Celine Martin and Jeff Mirviss, to its…

Read MoreCONMED Corporation Appoints Celine Martin and Jeff Mirviss to Board of Directors

Cosette Pharmaceuticals Names David Bell Chief Commercial Officer for Brands Division

Cosette Pharmaceuticals Enhances Commercial Leadership With Addition of Industry Veteran David Bell Cosette Pharmaceuticals has announced the appointment of David Bell as Chief Commercial Officer for its branded business, marking another step in the company’s ongoing effort to strengthen its…

Read MoreCosette Pharmaceuticals Names David Bell Chief Commercial Officer for Brands Division

Sustained Therapeutics Showcases Positive Phase 2 ST-01 Results at AUA 2026 Annual Meeting

Sustained Therapeutics Highlights Positive Mid-Stage Clinical Outcomes for Its Investigational Therapy ST-01 Sustained Therapeutics has reported additional positive findings from its Phase 2 clinical study evaluating ST-01, the company’s proprietary non-opioid sustained-release therapy for men suffering from chronic scrotal content…

Read MoreSustained Therapeutics Showcases Positive Phase 2 ST-01 Results at AUA 2026 Annual Meeting

Sumitomo Pharma America Presents AUA 2026 Data on Vibegron in Older Men With OAB and BPH

Sumitomo Pharma America Presents AUA 2026 Data Showing Vibegron Benefits in Older Men With Overactive Bladder and BPH Sumitomo Pharma America presented new clinical and real-world evidence from its urology and oncology portfolios at the American Urological Association 2026 Annual…

Read MoreSumitomo Pharma America Presents AUA 2026 Data on Vibegron in Older Men With OAB and BPH

Parabilis Medicines and Regeneron Pharmaceuticals Partner to Develop Novel Antibody-Helicon™ Conjugates

Parabilis Medicines Partners With Regeneron Pharmaceuticals to Develop Antibody-Helicon™ Conjugates Across Multiple Diseases Parabilis Medicines has entered into a major strategic research collaboration with Regeneron Pharmaceuticals aimed at advancing a new generation of targeted medicines designed to tackle some of…

Read MoreParabilis Medicines and Regeneron Pharmaceuticals Partner to Develop Novel Antibody-Helicon™ Conjugates

Genentech Wins FDA Approval for Tecentriq in ctDNA-Guided Adjuvant Treatment of Muscle-Invasive Bladder Cancer

Genentech Receives FDA Approval for Tecentriq in ctDNA-Guided Treatment of Muscle-Invasive Bladder Cancer Genentech announced that the U.S. Food and Drug Administration has approved both Tecentriq and Tecentriq Hybreza as adjuvant treatments for adult patients with muscle-invasive bladder cancer (MIBC)…

Read MoreGenentech Wins FDA Approval for Tecentriq in ctDNA-Guided Adjuvant Treatment of Muscle-Invasive Bladder Cancer